JP2023527741A5 - - Google Patents

Info

Publication number
JP2023527741A5
JP2023527741A5 JP2022570279A JP2022570279A JP2023527741A5 JP 2023527741 A5 JP2023527741 A5 JP 2023527741A5 JP 2022570279 A JP2022570279 A JP 2022570279A JP 2022570279 A JP2022570279 A JP 2022570279A JP 2023527741 A5 JP2023527741 A5 JP 2023527741A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
use according
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032808 external-priority patent/WO2021236543A1/en
Publication of JP2023527741A publication Critical patent/JP2023527741A/ja
Publication of JP2023527741A5 publication Critical patent/JP2023527741A5/ja
Pending legal-status Critical Current

Links

JP2022570279A 2020-05-19 2021-05-17 アミロイドーシスの治療 Pending JP2023527741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027194P 2020-05-19 2020-05-19
US63/027,194 2020-05-19
PCT/US2021/032808 WO2021236543A1 (en) 2020-05-19 2021-05-17 Treatment for amyloidosis

Publications (2)

Publication Number Publication Date
JP2023527741A JP2023527741A (ja) 2023-06-30
JP2023527741A5 true JP2023527741A5 (https=) 2024-05-23

Family

ID=78708017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570279A Pending JP2023527741A (ja) 2020-05-19 2021-05-17 アミロイドーシスの治療

Country Status (12)

Country Link
US (1) US20230210846A1 (https=)
EP (1) EP4138837A4 (https=)
JP (1) JP2023527741A (https=)
KR (1) KR20230013102A (https=)
CN (1) CN116133661A (https=)
AU (1) AU2021273731A1 (https=)
BR (1) BR112022023486A2 (https=)
CA (1) CA3183746A1 (https=)
IL (1) IL298297A (https=)
MX (1) MX2022014468A (https=)
TW (1) TW202207931A (https=)
WO (1) WO2021236543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114877A1 (en) * 2021-12-15 2023-06-22 Recurium Ip Holdings, Llc Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200108301A (ko) * 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
WO2019199899A1 (en) * 2018-04-09 2019-10-17 Case Western Reserve University Bioink and crosslinkable support medium for printing
US10659731B2 (en) * 2018-04-10 2020-05-19 Facebook, Inc. Automated cinematic decisions based on descriptive models
CA3095513A1 (en) * 2018-04-10 2019-10-17 DDP Specialty Electronic Materials US, Inc. Dispenser for can with fixed valve stem housing

Similar Documents

Publication Publication Date Title
JP2012532889A5 (https=)
JP2023530166A5 (https=)
JP2013542990A5 (https=)
JP2023527741A5 (https=)
JP2008500987A5 (https=)
CA2569077C (en) Combinations comprising antimuscarinic agents and corticosteroids
JP2014510064A5 (https=)
JP2002525317A5 (https=)
EA201691126A1 (ru) Находящаяся под давлением стабильная аэрозольная композиция комбинации гликопиррония бромида и формотерола в форме раствора
JP6250542B2 (ja) エクトインの治療的使用
JP2012528792A5 (https=)
RU2018103940A (ru) Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза
HRP20180944T1 (hr) Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
JP2015506983A5 (https=)
JP2024525567A5 (https=)
JP2006502160A5 (https=)
US5407926A (en) Ophthalmic composition
JPH11130679A5 (https=)
RU2015154037A (ru) Применение антагониста рецептора NK-1 серлопитанта при зуде
JP2019528316A5 (https=)
JP2021534201A5 (https=)
AR097078A1 (es) Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto
JP2006518382A5 (https=)
EP2701744A1 (en) Combination therapy
Pirker et al. Angioedema and dysphagia caused by contact allergy to inhaled budesonide